Ukko Overview
Ukko's mission is to improve the lives of people with food allergies and sensitivities. Ukko uses immunology, machine learning, and protein engineering to make measurably better and safer proteins for use in food and therapeutics. Ukko does this by designing and controlling the molecular interactions between allergen proteins and the immune system. Ukko's technology uses samples from patients and machine learning to guide the engineering of superior proteins that can be incorporated into food products and therapeutics. These proteins maintain or improve beneficial properties (taste, nutritional value, yield, and physicochemical and mechanical properties) but do not trigger an immune response. Ukko's initial product pipeline includes celiac-safe gluten proteins, allergy-safe and therapeutic peanut proteins, as well as a pipeline of additional allergen proteins.
Cumulative Funding Raised Over Time ($)
$40.0MJan 2021
$47.7MJul 2017
$47.7MJun 2025
Latest News
growth-positive
"פיתחנו גלוטן בטוח עבור חולי צליאק שמספרם מכפיל את עצמו כל כמה שנים" כלכליסט
Ukko, an American-Israeli company, has developed safe gluten and proteins for individuals with food allergies. The company uses genetic engineering to produce safe proteins that retain their beneficial properties while eliminating the harmful ones. Ukko focuses on addressing gluten sensitivity, a condition that affects individuals with celiac disease. The company has also developed medications for other food allergies, such as nut allergies. Ukko has raised $48 million in funding and is supported by various companies, including Baer. The goal of Ukko is to create a healthier and safer world for everyone.
Customers
growth-positive
The Israeli startup trying to reimagine wheat
Ukko, an Israeli startup, is using artificial intelligence to redesign gluten and peanut proteins to help those with celiac disease and peanut allergies. The company has engineered a gluten protein that does not contain the component that triggers an immune response in celiac patients. In addition, Ukko is working on modifying peanut proteins to neutralize their ability to trigger allergic reactions. The company has raised $40 million in a funding round led by Bayer and Khosla Ventures. The funds will be used to move from initial development to clinical trials within the next two years.
InvestmentExpand
growth-positive
Ukko raises $40 million to develop solutions for food allergies and sensitivities
Israeli biotechnology startup Ukko has completed a $40 million series B funding round led by Leaps by Bayer. The company uses patient data, machine learning, and AI to engineer food proteins for food products, plants, and therapeutics. The funding will be used to expand Ukkos teams in the U.S. and Israel and accelerate the development of unique food proteins, with a focus on peanut and gluten-related disorders. Ukko also plans to conduct clinical trials in Israel for medicine to fight against allergies. The company was founded in 2016 by Anat Binur and Yanay Ofran.
InvestmentExpand
growth-positive
Ukko raises $40 million to develop solutions for food allergies and sensitivities
Israeli biotechnology startup Ukko has completed a $40 million series B funding round led by Leaps by Bayer. The company uses patient data, machine learning, and AI to engineer food proteins that can be incorporated into food products, plants, and therapeutics. The funding will be used to expand Ukkos teams in the U.S. and Israel and accelerate the development of unique food proteins, with a focus on peanut and gluten-related disorders. Ukko plans to manufacture bread and pastries that are safe for people with Celiac disease and conduct clinical trials for medicine to fight against allergies. The company was founded in 2016 by Anat Binur and Yanay Ofran.
InvestmentExpand
growth-positive
Ukko scores $40m in Bayer-led Series B for anti-allergy foodtech
Israeli biotech startup Ukko has raised $40 million in a Series B round led by Bayers corporate venture unit, Leaps by Bayer. The funding will be used to develop functional food ingredients and therapeutics to eliminate food allergies and sensitivities, with an initial focus on gluten and peanut allergies. Ukkos approach combines artificial intelligence and bio-engineering to alter food proteins in a way that eliminates their ability to trigger allergies while maintaining their nutritional characteristics. The company aims to enter clinical trials for its investigational therapeutic for peanut allergy. The funding round included participation from several investors, including Continental Grain Company, PeakBridge Ventures, Skyviews Life Science, and Fall Line Capital.
Investment
| Sector | Agriculture & Food Technologies |
Funding
| Total funding | $47.7M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 3 |
| Investors | 11 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | www.ukko.us/ |
Locations
HaMada Street 12, Rehovot, Israel
1845 El Camino Real, Palo Alto, CA 94306, USA
Photos & Videos
No files yet
Ukko Business
Business models
B2B
Product stage
R&D
Employees
51-200
Sector
Agriculture & Food TechnologiesFood TechNovel Food & IngredientsTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsAgriculture & FoodProcessed FoodsIngredientsCore Technology
Artificial IntelligenceBiologicalsTags (12)
biotechnologyfoodtechfood-ingredientsmolecular-biologyconsumersbig-datapharmaceuticalstherapeuticsimmunologyallergyproteinsartificial-intelligenceGeographic Markets
IsraelUnited StatesUkko Financials
$47.7M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
A
Funding stage
3
Total rounds
11
Investors
Cumulative Funding Raised Over Time ($)
$40.0MJan 2021
$47.7MJul 2017
$47.7MJun 2025
Private Equity Funding
A Round
Jun 2025
Undisclosed
Sanara Capital
B Round
Jan 2021
$40M
Leaps by Bayer (Lead)
,
Khosla Ventures, PeakBridge , Fall Line Capital, Continental Grain Company, Skyviews LifeScience, Innovation Endeavors, Marc Benioff
A Round
Jul 2017
$7.7M
Marc Benioff, Izhar Armony, Khosla Ventures, Innovation Endeavors, Slow Ventures
Ukko Lifecycle
Cumulative Funding Raised Over Time
$40.0MJan 2021
$47.7MJul 2017
$47.7MJun 2025
All Events
A Round
Jun 2025
Undisclosed
Sanara Capital
B Round
Jan 2021
$40M
Leaps by Bayer (Lead)
,
Khosla Ventures, PeakBridge , Fall Line Capital, Continental Grain Company, Skyviews LifeScience, Innovation Endeavors, Marc Benioff
A Round
Jul 2017
$7.7M
Marc Benioff, Izhar Armony, Khosla Ventures, Innovation Endeavors, Slow Ventures
Ukko News
6 articles
growth-positive
"פיתחנו גלוטן בטוח עבור חולי צליאק שמספרם מכפיל את עצמו כל כמה שנים" כלכליסט
Ukko, an American-Israeli company, has developed safe gluten and proteins for individuals with food allergies. The company uses genetic engineering to produce safe proteins that retain their beneficial properties while eliminating the harmful ones. Ukko focuses on addressing gluten sensitivity, a condition that affects individuals with celiac disease. The company has also developed medications for other food allergies, such as nut allergies. Ukko has raised $48 million in funding and is supported by various companies, including Baer. The goal of Ukko is to create a healthier and safer world for everyone.
Customers
growth-positive
The Israeli startup trying to reimagine wheat
Ukko, an Israeli startup, is using artificial intelligence to redesign gluten and peanut proteins to help those with celiac disease and peanut allergies. The company has engineered a gluten protein that does not contain the component that triggers an immune response in celiac patients. In addition, Ukko is working on modifying peanut proteins to neutralize their ability to trigger allergic reactions. The company has raised $40 million in a funding round led by Bayer and Khosla Ventures. The funds will be used to move from initial development to clinical trials within the next two years.
InvestmentExpand
growth-positive
Ukko raises $40 million to develop solutions for food allergies and sensitivities
Israeli biotechnology startup Ukko has completed a $40 million series B funding round led by Leaps by Bayer. The company uses patient data, machine learning, and AI to engineer food proteins for food products, plants, and therapeutics. The funding will be used to expand Ukkos teams in the U.S. and Israel and accelerate the development of unique food proteins, with a focus on peanut and gluten-related disorders. Ukko also plans to conduct clinical trials in Israel for medicine to fight against allergies. The company was founded in 2016 by Anat Binur and Yanay Ofran.
InvestmentExpand
growth-positive
Ukko raises $40 million to develop solutions for food allergies and sensitivities
Israeli biotechnology startup Ukko has completed a $40 million series B funding round led by Leaps by Bayer. The company uses patient data, machine learning, and AI to engineer food proteins that can be incorporated into food products, plants, and therapeutics. The funding will be used to expand Ukkos teams in the U.S. and Israel and accelerate the development of unique food proteins, with a focus on peanut and gluten-related disorders. Ukko plans to manufacture bread and pastries that are safe for people with Celiac disease and conduct clinical trials for medicine to fight against allergies. The company was founded in 2016 by Anat Binur and Yanay Ofran.
InvestmentExpand
growth-positive
Ukko scores $40m in Bayer-led Series B for anti-allergy foodtech
Israeli biotech startup Ukko has raised $40 million in a Series B round led by Bayers corporate venture unit, Leaps by Bayer. The funding will be used to develop functional food ingredients and therapeutics to eliminate food allergies and sensitivities, with an initial focus on gluten and peanut allergies. Ukkos approach combines artificial intelligence and bio-engineering to alter food proteins in a way that eliminates their ability to trigger allergies while maintaining their nutritional characteristics. The company aims to enter clinical trials for its investigational therapeutic for peanut allergy. The funding round included participation from several investors, including Continental Grain Company, PeakBridge Ventures, Skyviews Life Science, and Fall Line Capital.
Investment
growth-positive
Synthetic Biology Partners With AI To Delete Food Allergies
Israeli startup Ukko has raised $40 million in a Series B funding round led by Leaps by Bayer to develop hypoallergenic proteins for people with food allergies. Ukko aims to create proteins that cannot cause allergic reactions, focusing first on peanuts and gluten. For peanuts, Ukko plans to develop hypoallergenic peanut proteins for immunotherapy, allowing those with severe allergies to build up tolerance. For gluten, Ukko aims to create hypoallergenic protein ingredients for food, making gluten-rich dishes safe for people with gluten sensitivities and celiac disease. The funding will support Ukkos efforts to advance its peanut proteins into clinical testing and prepare its products for market entry.
Investment
Ukko Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 51 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Ukko Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | video or image, markets |
| BI Verification | Yamila Silbert |
| Registrar ID | 515685550 |
| Crunchbase | ukko |
| Creator | Hilla Gorokhovsky |
| Creator email | hilla.gorokhovsky@sncentral.org |
| Last updater | Ortal Wein |
| Updater email | ortalw@sncentral.org |
| Last update | 2022-09-04T00:00:00.000Z |
| Created | 2019-02-17T00:00:00.000Z |
| Claimed | Yes |